Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186268 | 0.90 | MEN1 (0.46) | SMN1; SMN2MAPTGAAL3MBTL1NPC1 | |
| SCHEMBL16824933 | 0.87 | MAPT (0.43) | SMN1; SMN2MAPTGAANPC1KDM4E | |
| SCHEMBL18186167 | 0.85 | GFER (0.44) | MAPTGAALMNANR1H2 | |
| SCHEMBL18186404 | 0.85 | AOC3 (0.38) | SMN1; SMN2MAPTGAAAOC3NPC1 | |
| SCHEMBL18186403 | 0.85 | NR1H2 (0.37) | SMN1; SMN2MAPTGAAKDM4EMEN1 | |
| SCHEMBL17536983 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTGAAAOC3NPC1 | |
| SCHEMBL18186287 | 0.84 | HTR2C (0.36) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL18186347 | 0.84 | AOC3 (0.38) | SMN1; SMN2MAPTGAAAOC3KDM4E | |
| SCHEMBL16824900 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTNPC1MEN1KMT2A | |
| SCHEMBL8174063 | 0.80 | KMT2A (0.40) | MAPTGAAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3484887-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | Almac Discovery Limited (GB) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018011569-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-01-18 | — | — | WO | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| EP-2984090-B1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | WEE1, WEE2, NME1 | SMN1; SMN2 4526/4885MAPT 3926/4885GAA 2022/4885 |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | WEE1, WEE2, PPME1 | SMN1; SMN2 4569/4885MAPT 3141/4885GAA 2201/4885 |
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | WEE1, WEE2, PPME1 | SMN1; SMN2 4583/4885MAPT 3571/4885GAA 2447/4885 |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | SMN1; SMN2 4422/4885MAPT 3728/4885GAA 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.